WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 240

Legislative bill overview

SB 240 establishes a framework for research into ibogaine, a naturally occurring alkaloid found in West African plants, within Kentucky. The bill appears to create pathways for controlled study of this substance, which has shown preliminary promise in addiction treatment research but remains a Schedule I controlled substance under federal law.

Why is this important

Ibogaine has generated significant scientific interest for potential treatment of opioid and other substance use disorders, particularly given Kentucky's ongoing struggles with addiction. However, federal legal restrictions severely limit research opportunities, making state-level authorization potentially valuable for advancing understanding of this compound's therapeutic applications.

Potential points of contention

  • Federal-state legal conflict: Ibogaine remains federally scheduled as a controlled substance, creating tension between state authorization and federal prohibition that could complicate implementation
  • Safety and efficacy concerns: Limited human clinical trial data exists; potential cardiovascular risks and adverse effects require careful evaluation before broader research expansion
  • Research infrastructure and costs: Establishing ibogaine research protocols requires specialized facilities, DEA licensing, and significant funding—questions remain about resource allocation and practical feasibility

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.